Prime Medicine Inc. (PRME)
The price, the headline numbers and the latest news, in one place.
Prime Medicine Inc. (PRME) Stock Price, Analysis & Data
| Bid | 2.24 |
| Market Cap | 614.87M |
| Revenue (ttm) | 4.07M |
| Net Income (ttm) | -187.89M |
| 2.31 | |
| -1.05 | |
| n/a | |
| -3.83 | |
| P/B (ttm) | 15.07 |
| P/S (ttm) | 150.96 |
| Earnings Date | Nov 6, 2026 |
| Ask | 3.71 |
| Volume | 3,585,997 |
| Avg. Volume (20D) | 3,375,606 |
| Open | 3.28 |
| Previous Close | 3.24 |
| Day's Range | 3.24 - 3.48 |
| 52-Week Range | 2.67 - 6.94 |
| Analyst | Buy |
| Price Target | 8 (135.99%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting i...
Financial Performance
In 2025, Prime Medicine's revenue was 4.63M, an increase of 55.28% compared to the previous year's 2.98M. Earnings were -201.14M, an increase of 2.69%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for PRME stock is "Buy". The 12-month stock price forecast is 8, which is upside of 135.99% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.15M misses estimates by $0, with 3.50% YoY growth.
- EPS of -0.24 exceeds estimates by 0.02, with 41.46% YoY growth.
Analysts project revenue of ... Upgrade
